Acorda Therapeutics (NASDAQ:ACOR) had its price objective decreased by stock analysts at Leerink Swann to $18.00 in a research report issued to clients and investors on Wednesday, November 15th. The firm currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price objective points to a potential downside of 13.46% from the company’s current price. Leerink Swann also issued estimates for Acorda Therapeutics’ Q1 2018 earnings at $0.69 EPS, Q2 2018 earnings at $0.84 EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at $0.77 EPS and FY2019 earnings at ($2.18) EPS.
Other analysts have also recently issued research reports about the company. Janney Montgomery Scott reaffirmed a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research report on Wednesday, August 30th. ValuEngine raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 26th. BidaskClub lowered Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $18.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, October 31st. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Acorda Therapeutics has an average rating of “Hold” and a consensus target price of $21.47.
Acorda Therapeutics (NASDAQ ACOR) opened at $20.80 on Wednesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. Acorda Therapeutics has a 1-year low of $13.60 and a 1-year high of $33.00.
Several institutional investors and hedge funds have recently made changes to their positions in ACOR. FMR LLC lifted its stake in shares of Acorda Therapeutics by 5.2% in the 2nd quarter. FMR LLC now owns 6,998,913 shares of the biopharmaceutical company’s stock valued at $137,879,000 after purchasing an additional 348,895 shares during the period. Vanguard Group Inc. lifted its stake in shares of Acorda Therapeutics by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock valued at $84,871,000 after purchasing an additional 168,571 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Acorda Therapeutics by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock valued at $62,813,000 after purchasing an additional 283,091 shares during the period. State Street Corp lifted its stake in shares of Acorda Therapeutics by 52.4% in the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after purchasing an additional 851,290 shares during the period. Finally, RA Capital Management LLC lifted its stake in shares of Acorda Therapeutics by 83.8% in the 2nd quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock valued at $17,735,000 after purchasing an additional 410,431 shares during the period.
TRADEMARK VIOLATION WARNING: “Acorda Therapeutics (NASDAQ:ACOR) Price Target Lowered to $18.00 at Leerink Swann” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/12/04/leerink-swann-trims-acorda-therapeutics-inc-acor-target-price-to-18-00.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.